Ipidacrine is a reversible cholinesterase inhibitor primarily used in medical settings to treat myasthenia gravis, an autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. By inhibiting the breakdown of acetylcholine, it enhances cholinergic transmission at neuromuscular junctions, improving muscle strength and reducing symptoms such as ptosis, dysphagia, and generalized weakness.

Additionally, ipidacrine serves as a cognitive enhancer and neuroprotective agent. It is prescribed to improve memory, attention, and mental clarity in patients with cognitive impairments, such as those caused by Alzheimer's disease, dementia, or other neurodegenerative conditions. The compound supports better communication between nerve cells and overall cognitive function.

Ipidacrine is also utilized in stroke recovery to aid in restoring neurological functions and reducing post-stroke deficits. Its neuroprotective properties promote nerve regeneration and protect neurons from damage, making it valuable for various central nervous system disorders. In some cases, it may help address symptoms associated with depression and anxiety by positively influencing mood and mental well-being.